Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study Academic Article uri icon

Overview

MeSH Major

  • Anemia, Diamond-Blackfan
  • Benzoates
  • Iron Chelating Agents
  • Myelodysplastic Syndromes
  • Thalassemia
  • Triazoles
  • beta-Thalassemia

abstract

  • Deferasirox is effective for reducing iron burden with a defined, clinically manageable safety profile in patients with various transfusion-dependent anaemias. There were no disease-specific adverse events. Once differences in transfusional iron intake are accounted for, dose-dependent changes in LIC or serum ferritin are similar in MDS and other disease groups.

authors

publication date

  • February 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2268958

Digital Object Identifier (DOI)

  • 10.1111/j.1600-0609.2007.00985.x

PubMed ID

  • 18028431

Additional Document Info

start page

  • 168

end page

  • 76

volume

  • 80

number

  • 2